Iron Deficiency Anemia – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Iron Deficiency Anemia – Pipeline Review, H1 2018’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia

– The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects

– The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akebia Therapeutics Inc

Galenica Ltd

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Galenica Ltd

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Iron Deficiency Anemia - Drug Profiles

AKB-5343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron isomaltoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-8679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia - Dormant Projects

Iron Deficiency Anemia - Product Development Milestones

Featured News & Press Releases

Nov 07, 2017: U.S. FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis

Nov 02, 2017: Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease

Oct 30, 2017: Rockwell Medical Announces Two Triferic Poster Presentations at American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 13, 2017: Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 10, 2017: Shield Therapeutics: Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study

Sep 06, 2017: Shield Therapeutics: US Composition of Matter Patent

Jul 12, 2017: Vifor Pharma Announces Three Outcomes Trials in Heart Failure and Iron Deficiency

Jun 22, 2017: Shield Therapeutics: Biomarker data presented at British Society of Gastroenterology demonstrates the potential effect of ferric maltol in patients

Apr 24, 2017: American Regent Announces Enrollment of First Patient in Phase 3 Trial to Investigate Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Mar 20, 2017: Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia to its Medicare Part D Plan Formularies

Mar 08, 2017: Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia (ferric citrate) Tablets

Feb 13, 2017: Pharmacosmos's Diafer accepted for use in NHS Scotland

Jan 12, 2017: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology

Jan 08, 2017: Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference

Jan 06, 2017: Shield Therapeutics Provides Business Update

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Iron Deficiency Anemia – Pipeline by Akebia Therapeutics Inc, H1 2018

Iron Deficiency Anemia – Pipeline by Galenica Ltd, H1 2018

Iron Deficiency Anemia – Pipeline by Novartis AG, H1 2018

Iron Deficiency Anemia – Pipeline by Panion & Bf Biotech Inc, H1 2018

Iron Deficiency Anemia – Pipeline by Pharmacosmos AS, H1 2018

Iron Deficiency Anemia – Pipeline by Pieris Pharmaceuticals Inc, H1 2018

Iron Deficiency Anemia – Pipeline by Rockwell Medical Inc, H1 2018

Iron Deficiency Anemia – Pipeline by Shield Therapeutics Plc, H1 2018

Iron Deficiency Anemia – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports